Scientists have identified a key protein that helps pancreatic tumors build a protective fortress against treatment, opening the door to a new clinical trial that aims to make these deadly cancers vulnerable to existing therapies. Researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have pinpointed the interleukin-1 receptor accessory protein, or IL1RAP, as a master orchestrator of the tumor’s supportive network. Their findings, published in the journal JCI Insight, have already led to a pioneering neoadjuvant clinical trial for patients with operable pancreatic cancer.
Pancreatic cancer is notoriously difficult to treat because its tumor microenvironment acts like a shield. This dense mix of fibrotic tissue, immune-suppressing cells, and supportive fibroblasts blunts the effects of chemotherapy and immunotherapy. The research team discovered that IL1RAP functions as a critical hub, connecting malignant cells with immune cells and fibroblasts in a coordinated system that promotes tumor survival and resistance. Unlike prior efforts that targeted single cell types, blocking IL1RAP disrupts multiple inflammatory signals at once. In preclinical experiments, this inhibition reduced tumor-promoting fibrosis, decreased immune-suppressive myeloid cells, and reactivated T cells, the body’s frontline cancer fighters. The result was a significant improvement in how tumors responded to combination chemoimmunotherapy.
“This strategy seeks to convert an immune-excluded and therapy-resistant environment into one that is immune-permissive and susceptible to existing treatment options,” said Dr. Jashodeep Datta, the study’s lead investigator and a pancreatic surgical oncologist. The approach represents a paradigm shift: instead of attacking cancer cells alone, it reprograms the entire tumor ecosystem. The effect is twofold, modulating the immune landscape while sensitizing the cancer cells themselves to treatment.
Building on these results, Sylvester Comprehensive Cancer Center has launched a groundbreaking neoadjuvant clinical trial that combines IL1RAP-targeted therapy with chemoimmunotherapy in patients before surgery. This trial design allows researchers to analyze tumor samples before and after treatment, offering a rare window into how the therapy reshapes the tumor’s biology in real time. Co-author Dr. Peter Hosein noted that this integrative approach bridges laboratory discoveries with patient care, illustrating a clear path from bench to bedside. The research is supported by a competitive Translational Research Grant from the V Foundation, underscoring its scientific promise.
While recent advances in KRAS-targeted therapies have extended survival for some metastatic patients, most people with operable pancreatic cancer have yet to benefit from such innovations. The IL1RAP-directed strategy offers a complementary path, targeting the tumor’s inflammatory backbone rather than a single genetic mutation. As the clinical trial progresses, researchers hope to identify biomarkers that predict response and uncover any emerging resistance pathways. For a patient population with limited options and a poor prognosis, this new approach could mark a turning point, transforming the outlook for one of the deadliest cancers.